Inside the Bottle brings you the latest supplement industry news in this monthly roundup
If you are having trouble reading this email, read the online version
 
Inside the Bottle
 
image
 
FDA chief wants listing requirement—article
FDA Commissioner Robert Califf, M.D., revealed he supports a requirement that manufacturers of dietary supplements list their products with his agency. The Natural Products Association and the Council for Responsible Nutrition reacted strongly—taking opposing sides of the issue. Read more here.
  Heart health category: Quiet, steady growth—and intriguing potential – spotlight analysis
Cardiovascular health supplements growth can be described in just the terms you would like your cardiologist to describe your EKG: “solid, but not exciting.” Stay on top of the category data from SPINS and further analytics from Nutrition Business Journal in the quick analysis from ITB. Read more here.
Amazon bans NMN in supplements—article
Sellers can no longer sell the anti-aging ingredient as a dietary supplement after March 13, 2023, after the FDA ruled it “a drug, or drug ingredient, that requires FDA approval.” Natural Products Association President and CEO Dan Fabricant called it an “unfortunate development,” and noted that “FDA’s habitual neglectful abuse of the law should scare anyone in the dietary supplement industry.” Read more here.
  Missing: Clinical trials—and health equity—among insurance providers—blog
The country’s largest health insurance provider doesn’t mention clinical trials within its new Framework for Health Equity 2022-2032. “It is time we place greater accountability on our government institutions to ensure health data and the resultant evidence-based treatment is relevant to all—and for dietary supplement products to embrace this critical mandate,” according to Radicle Science.
Major network marketing companies not immune to sales decline—article
Herbalife Nutrition Ltd.’s yearly sales sunk by 10.4% year-over-year. NuSkin’s fourth quarter sales dropped by more than 22%, year-over-year. Find out how inflation, pandemic and the war in Ukraine impacted other MLM heavy hitters, including USANA Health Sciences Inc.—and how they still recorded profits. Read more here.
  Delta-9-THCO and delta-8-THCO are not hemp, says DEA—article
The Drug Enforcement Administration has concluded that the two synthetic cannabinoids do not meet the definition of hemp and are controlled substances. This does not impact the legal status of delta-8 THC, which can be found naturally in hemp. Find out why the Hemp Industries Association actually agrees with the government this time around. Read more here.
 
 
ITB
  Inside the Bottle unites companies from across the supplement supply chain to advocate for a transparent, collaborative supplement industry that supports consumer health empowerment. #InsidetheBottle
 
 
PAID CONTENT
Meet our Inside the Bottle partners
Childlife
 
PLT
 
Radical Science
 
SGS
SoftGel
 
SPINS
 
Vytalogy
 
image
 
Produced by
 
 
By Informa Markets
 
 
This email was sent to you by the Informa Markets Division of Informa PLC (Privacy Policy).
Informa PLC's registered office is 5 Howick Place, London SW1P 1WG.
Registered in England and Wales. Number 8860726.
 
If you do not wish to receive further information from us, please click here.
Alternatively, to contact our data services team to have your details or preferences updated please email imdatateam@informa.com.